Your browser doesn't support javascript.
loading
Development, Strategies, and Challenges for Tularemia Vaccine.
Moradkasani, Safoura; Maurin, Max; Farrokhi, Amir Salek; Esmaeili, Saber.
Afiliación
  • Moradkasani S; National Reference Laboratory for Plague, Tularemia and Q Fever, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Akanlu, KabudarAhang, Hamadan, Iran.
  • Maurin M; Department of Epidemiology and Biostatics, Research Centre for Emerging and Reemerging Infectious Diseases, Pasteur Institute of Iran, Tehran, Iran.
  • Farrokhi AS; CNRS, Grenoble INP, CHU Grenoble Alpes, TIMC-IMAG, Universite Grenoble Alpes, 38000, Grenoble, France.
  • Esmaeili S; Department of Immunology, Pasteur Institute of Iran, Tehran, Iran.
Curr Microbiol ; 81(5): 126, 2024 Apr 02.
Article en En | MEDLINE | ID: mdl-38564047
ABSTRACT
Francisella tularensis is a facultative intracellular bacterial pathogen that affects both humans and animals. It was developed into a biological warfare weapon as a result. In this article, the current status of tularemia vaccine development is presented. A live-attenuated vaccine that was designed over 50 years ago using the less virulent F. tularensis subspecies holarctica is the only prophylactic currently available, but it has not been approved for use in humans or animals. Other promising live, killed, and subunit vaccine candidates have recently been developed and tested in animal models. This study will investigate some possible vaccines and the challenges they face during development.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tularemia / Vacunas Límite: Animals / Humans Idioma: En Revista: Curr Microbiol Año: 2024 Tipo del documento: Article País de afiliación: Irán

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tularemia / Vacunas Límite: Animals / Humans Idioma: En Revista: Curr Microbiol Año: 2024 Tipo del documento: Article País de afiliación: Irán